Cholestyramine

Synonyms: 考来烯胺; Cholestyramine resin; Colestyramine
Cholestyramine (Cholestyramine resin) 是一种具有口服活性的胆汁酸螯合剂,可上调肠道顶端钠依赖性胆汁酸转运体 (Apical sodium-dependent bile acid transporter) 和肝脏胆固醇 7α-羟化酶 (Cholesterol 7α-hydroxylase) 的表达,诱导肠道和肝脏胆固醇生成基因及肝脏脂肪生成基因的表达,促进胆汁酸和中性固醇介导的胆固醇逆向转运,减少肠道胆固醇吸收并诱导胆固醇外流,可用于冠状动脉疾病、动脉粥样硬化性心血管疾病及动脉粥样硬化的相关研究。
产品编号: MS-X90634 CAS No.: 11041-12-6
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
3-5 天
10g
询价
3-5 天
25g
询价
3-5 天
50g
询价
3-5 天
100g
询价
3-5 天
> 100g
询价
询价

产品描述

Cholestyramine (Cholestyramine resin) 是一种具有口服活性的胆汁酸螯合剂,可上调肠道顶端钠依赖性胆汁酸转运体 (Apical sodium-dependent bile acid transporter) 和肝脏胆固醇 7α-羟化酶 (Cholesterol 7α-hydroxylase) 的表达,诱导肠道和肝脏胆固醇生成基因及肝脏脂肪生成基因的表达,促进胆汁酸和中性固醇介导的胆固醇逆向转运,减少肠道胆固醇吸收并诱导胆固醇外流,可用于冠状动脉疾病、动脉粥样硬化性心血管疾病及动脉粥样硬化的相关研究。

生物实验数据

生物活性 Cholestyramine (Cholestyramine resin) is an orally active bile acid sequestrant that upregulates the expression of the intestinal apical sodium-dependent bile acid transporter and hepatic cholesterol 7α-hydroxylase, induces the expression of intestinal and hepatic cholesterogenic genes and hepatic lipogenic genes, promotes bile acid- and neutral sterol-mediated reverse cholesterol transport, reduces intestinal cholesterol absorption, and induces cholesterol efflux, and can be used in research related to coronary artery disease, atherosclerotic cardiovascular disease, and atherosclerosis.
体外研究
(In Vitro)

Cholestyramine (0.1-50 μg/mL; 48 h) 可呈剂量依赖性地促进永生化微血管内皮细胞 HMEC-1 的胆固醇外流,在 50 μg/mL 浓度下孵育 48 小时后,细胞胆固醇负荷降低 66%。

体内研究
(In Vivo)

Cholestyramine (2%;通过饮食口服;自由采食;4 周) 在血脂正常的雄性 C57BL/6 小鼠中进行补充,会改变肠道和肝脏中胆汁酸、胆固醇及甘油三酯稳态相关基因的表达,降低血清胆汁酸、甘油三酯和非酯化脂肪酸水平,并增加粪便中胆汁酸、脂质和非酯化脂肪酸的排泄量,且不影响体重或肝脏酶水平。
Cholestyramine (2%;通过饮食口服;自由采食;4 周) 联合 GSPE (250 mg/kg;口服;单次) 在正常血脂雄性 C57BL/6 小鼠中给予,可协同增强肝脏胆汁酸合成基因的表达,减轻 Cholestyramine 诱导的肝脏胆固醇及脂肪生成基因表达升高,且相比单独使用 Cholestyramine,能更显著降低血清甘油三酯水平。
Cholestyramine (2% (w/w);通过饮食口服;每日;14 天) 可通过增强胆汁酸和中性甾醇的粪便排泄,使野生型 C57BL/6J 小鼠在 24-48 h 内的巨噬细胞-粪便逆向胆固醇转运水平提升至原来的 3.6 倍;当与 rHDL 联合使用时,无叠加效应。

Animal Model: C57BL/6 (male, 8 weeks old)
Dosage: 2%
Administration: dietary supplementation; ad libitum; 4 weeks
Result: Showed no significant difference in body weight relative to control at any weekly time point over 4 weeks.
Robustly induced apical sodium-dependent bile acid transporter (Asbt) expression relative to control.
Significantly reduced ileal bile acid binding protein (Ibabp) and fibroblast growth factor 15 (Fgf15) expression relative to control.
Significantly increased expression of intestinal cholesterol synthesis genes 3-hydroxy-3-methylglutaryl-CoA synthase 1 (Hmgcs1) and 3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr), as well as scavenger receptor class b, member 1 (Scarb1) and low density lipoprotein receptor (Ldlr) relative to control.
Induced cholesterol 7α-hydroxylase (Cyp7a1) expression 8-fold relative to control.
Increased sterol 12α-hydroxylase (Cyp8b1) expression relative to control.
Decreased oxysterol 7α-hydroxylase (Cyp7b1) expression relative to control.
Significantly increased expression of hepatic cholesterol synthesis genes Hmgcs1 and Hmgcr, as well as sterol regulatory element binding protein 1c (Srebf1c) and its lipogenic target genes acetyl CoA carboxylase 1 (Acc1), fatty acid synthase (Fasn), and stearoyl CoA desaturase (Scd1) relative to control.
Reduced serum bile acid levels relative to control.
Reduced serum triglyceride levels by 56% relative to control.
Reduced serum non-esterified fatty acid levels relative to control.
Showed no change in serum cholesterol, alanine aminotransferase (ALT), or aspartate aminotransferase (AST) levels relative to control.
Increased fecal bile acid excretion relative to control.
Increased total fecal lipid excretion relative to control.
Increased fecal non-esterified fatty acid excretion relative to control.
Showed no change in fecal cholesterol excretion relative to control.
Animal Model: C57BL/6 (male, 8 weeks old)
Dosage: 2% (cholestyramine); 250 mg/kg (GSPE)
Administration: dietary supplementation; ad libitum; 4 weeks (cholestyramine); p.o.; single dose (GSPE)
Result: Robustly induced Asbt expression relative to control.
Significantly reduced Ibabp and Fgf15 expression relative to control.
Significantly increased expression of intestinal cholesterol synthesis genes Hmgcs1 and Hmgcr, as well as Acat2, Mttp, Scarb1, and Ldlr relative to control.
Induced Cyp7a1 expression nearly 13-fold relative to control.
Increased Cyp8b1 and sterol 27-hydroxylase (Cyp27a1) expression relative to control.
Showed no change in Cyp7b1 expression relative to control.
Attenuated the cholestyramine-induced increases in hepatic Hmgcs1, Hmgcr, Srebf1c, Acc1, Fasn, and Scd1 expression relative to cholestyramine alone.
Reduced serum bile acid levels to a greater extent than cholestyramine alone relative to control.
Reduced serum triglyceride levels by 66.7% relative to control (a 25% additional decrease compared to cholestyramine alone).
Reduced serum non-esterified fatty acid levels relative to control.
Showed no change in serum cholesterol, ALT, or AST levels relative to control.
Increased fecal bile acid excretion relative to control.
Increased total fecal lipid excretion relative to control.
Increased fecal non-esterified fatty acid excretion relative to control.
Showed no change in fecal cholesterol excretion relative to control.
Animal Model: C57BL/6J mice
Dosage: 2% (w/w)
Administration: p.o.; daily; 14 days
Result: Decreased intestinal cholesterol absorption by 24%.
Increased fecal bile acid excretion several fold.
Increased fecal neutral sterol excretion at 0-4 h, 4-24 h, and 24-48 h.
Increased overall macrophage-to-feces RCT by 2.2-fold (4-24 h) and 3.6-fold (24-48 h).
Increased fecal tracer excretion within bile acids by 3.9-fold (4-24 h) and 3.2-fold (24-48 h).
Increased fecal tracer excretion within neutral sterols at 4-24 h and 24-48 h.
Did not change baseline plasma free or total cholesterol or triglyceride levels.
Caused a decrease in plasma free cholesterol levels at 4 h and an increase at 24 h and 48 h when combined with a single dose of rHDL (100 mg/kg apoA-I-POPC).
Showed no additive effect on RCT when combined with rHDL.
性状 固体
颜色 White to off-white

化学信息

CAS No. 11041-12-6
别名 考来烯胺; Cholestyramine resin; Colestyramine

储存&溶解度

溶解度信息
H2O: < 0.1 mg/mL (insoluble)
DMSO: < 1 mg/mL (insoluble or slightly soluble)
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础